Is Enclomiphene Actually Dangerous?

The fear around enclomiphene almost always comes from the same place, which is someone mixing it up with clomiphene, and that confusion is worth untangling completely because the two compounds behave very differently inside the body.

Clomiphene, sold as Clomid, is not a single molecule. It is a mixture of two isomers, meaning two molecules with the same atoms arranged in different shapes, and those shapes produce opposite effects. About 62% of clomiphene is enclomiphene, and the remaining 38% is something called zuclomiphene. Enclomiphene blocks estrogen receptors in the hypothalamus and pituitary, which are the parts of your brain that monitor hormone levels and send signals down to your testes. When those receptors get blocked, your brain reads the situation as low estrogen, and it responds by increasing the output of something called LH and FSH, which are the hormones that tell your testes to produce more testosterone. Zuclomiphene does the opposite. It activates estrogen receptors rather than blocking them, and it lingers in the body for days rather than clearing in roughly ten hours the way enclomiphene does.

So you have one compound doing one job and another compound doing the opposite job, and you are taking both of them every time you take Clomid.

That matters because most of the side effects people associate with Clomid, the mood instability, the vision disturbances, the decreased libido, trace back to the estrogenic activity of zuclomiphene rather than to enclomiphene itself. The logic follows directly from the mechanism. If zuclomiphene is activating estrogen receptors and staying in your system for days, you are going to see estrogen-related effects accumulate over time. Enclomiphene, which clears quickly and blocks those same receptors, would not produce that pattern.

A 2024 study out of Baylor tested this directly in 66 men with secondary hypogonadism, comparing clomiphene and enclomiphene head to head. On clomiphene, 47% of men reported side effects. On enclomiphene, that number dropped to 13.8%, and the difference was statistically significant at p equals 0.001. Mood changes were reported by 9.1% of the clomiphene group and zero percent of the enclomiphene group. Decreased libido dropped from 33.3% on clomiphene down to 8.6% on enclomiphene. The estradiol data followed the same pattern, with clomiphene raising estradiol and enclomiphene actually lowering it, which is exactly what you would predict if the estrogenic activity of zuclomiphene is driving the hormonal noise.

A 2025 systematic review and meta-analysis that pooled data from 10 randomized controlled trials and 819 patients reported that 21% of participants across all groups experienced adverse events, but none of them were classified as severe. That is a meaningful distinction. Not zero side effects, but zero severe adverse events across the full published literature on this compound.

The efficacy data runs in the same direction. A 2013 study of 44 men taking 25 milligrams of enclomiphene for six weeks averaged 604 nanograms per deciliter of testosterone at the end of the treatment period, and blood markers for thyroid function, cortisol, ACTH, lipids, and bone turnover all remained unchanged, suggesting the compound was not creating downstream hormonal disruption in other systems. A 2014 study of 124 men over three months found testosterone rising from an average of 217 up to 472 nanograms per deciliter on the lower 12.5 milligram dose, and sperm counts were preserved at a mean of 176 million per milliliter, which matters because testosterone replacement therapy typically suppresses sperm production by shutting down the same LH and FSH signals that enclomiphene is designed to stimulate.

That last point is worth sitting with. Testosterone therapy and enclomiphene act on the same hormonal axis but in opposite directions. Testosterone therapy replaces the hormone from outside and suppresses the brain's signaling pathway in the process. Enclomiphene works upstream, stimulating the brain to produce the signal so the testes generate testosterone on their own. That is why sperm production stays intact on enclomiphene and typically does not on exogenous testosterone.

The honest limitations of the current evidence are worth naming. The longest follow-up in the published literature sits at around six months, so the data does not tell you what happens with extended use beyond that window. The FDA rejected the branded version of enclomiphene, sold under the name Androxal, but the rejection was over study design issues rather than safety findings. Because enclomiphene is currently available primarily through compounding pharmacies, product quality and dosing precision are not standardized the way they would be with an approved pharmaceutical, and that introduces a variable the published clinical trials do not account for.

If you are using or considering enclomiphene, the practical baseline is simple. Run bloodwork before you start to know where your testosterone, estradiol, LH, and FSH actually sit, and run it again after several weeks to confirm the compound is doing what it should. A drug working as intended and a drug failing silently can feel similar in the short term, and labs are how you tell the difference.

The broader point here is about how drug reputation actually forms. Clomiphene has decades of use and a well-documented side effect profile, and enclomiphene shares its name, its origin, and part of its molecular structure. That is enough for the reputation to transfer, even when the mechanism and the data tell a different story. Most of what people believe about enclomiphene is actually true about zuclomiphene, which is a compound they have never heard of and would not know to fear. The side effects belong to the piece of clomiphene that enclomiphene is specifically designed to exclude.

---

References

1. Saffati G, Kassab J, Orozco Rendon D, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Translational Andrology and Urology. 2024;139:1979-1987. Finding: Side effects: clomiphene 47% vs enclomiphene 13.8% p=0.001. Mood changes: 9.1% vs 0% p=0.03. Decreased libido: 33.3% vs 8.6% p=0.001. Estradiol decreased with enclomiphene, increased with clomiphene p=0.001. Source
2. Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. 2025. Finding: 10 RCTs, 819 patients. SERM therapy increased total testosterone by 273.76 ng/dL vs placebo p<0.01. 21% experienced adverse events; none were severe. Source
3. Wiehle RD, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism. BJU International. 2013;1128:1188-1200. Finding: 44 men, 6 weeks. 25 mg enclomiphene averaged 604 ng/dL testosterone. No effects on TSH, ACTH, cortisol, lipids, or bone markers. Source
4. Wiehle R, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia. Fertility and Sterility. 2014;1023:720-727. Finding: 124 men, 3 months. Testosterone rose from 217 to 472 ng/dL 12.5 mg. Sperm counts preserved mean 176 million/mL. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness